F-14/15, Orbit Mall, Civil Lines, Jaipur-302006
support@thetaxheaven.com
F-14/15, Orbit Mall, Civil Lines, Jaipur-302006 support@thetaxheaven.comJagsonpal Pharmaceuticals Ltd is one of India’s oldest and most reputed pharmaceutical companies, with a strong presence in the therapeutic segments of women’s health, pain management, and lifestyle-related drugs. Established in 1978, the company has consistently grown its footprint in the domestic pharma market and is also expanding globally.
In this article, we will explore Jagsonpal Pharmaceuticals’ share price target from 2025 to 2030 along with its fundamentals, business overview, and long-term investment outlook.
| Detail | Value |
|---|---|
| Current Price | ₹244.34 |
| Previous Close | ₹241.92 |
| Day's High | ₹249.00 |
| Day's Low | ₹241.92 |
| 52-Week High | ₹328.04 |
| 52-Week Low | ₹153.10 |
| Market Capitalization | ₹1,656 Cr |
| Beta (Volatility) | 1.65 |
| Book Value per Share | ₹29.59 |
| Face Value | ₹2 |
| Dividend Yield | 1.01% |
| VWAP | ₹245.89 |
| Volume | 135,799 |
| 20D Avg Volume | 168,433 |
| 20D Avg Delivery (%) | 38.92 |
| All-Time High | ₹328.04 |
| All-Time Low | ₹2.40 |
Jagsonpal Pharma is a trusted brand in the Indian pharmaceutical industry, well-known for producing quality formulations across various therapeutic areas. Its strong brand recall, legacy of over four decades, and diversified product portfolio make it a significant player in the mid-cap pharma segment.
Strong product presence in women’s health and lifestyle drugs.
Consistent dividend-paying company with a yield of 1.01%.
High Beta (1.65) indicates higher volatility compared to the market.
Market cap of ₹1,656 Cr places it in the mid-cap category with growth potential.
Expanding retail reach and improving distribution networks.
| Investor Type | Holding (%) |
|---|---|
| Promoters | 67.65% |
| Retail & Others | 30.12% |
| Foreign Institutions | 2.18% |
| Other Domestic Institutions | 0.05% |
The high promoter holding indicates confidence in the business, while growing retail participation shows increasing investor interest.
| Year | Minimum Target (₹) | Maximum Target (₹) |
|---|---|---|
| 2025 | 250 | 270 |
| 2026 | 280 | 320 |
| 2027 | 330 | 380 |
| 2028 | 390 | 440 |
| 2029 | 450 | 520 |
| 2030 | 530 | 600 |
These projections are based on the company’s business growth, sector demand, historical performance, and India’s growing pharmaceutical exports.
By 2025, Jagsonpal Pharma is expected to show stable performance.
Why?
Strong retail demand in pharma stocks.
Dividend-paying track record adds investor confidence.
Consistent product demand in lifestyle and women’s health.
Investment Advice: Suitable for medium-term investors; consider staggered buying.
In 2026, the company could benefit from expansion in formulations and export demand.
Why?
Pharma exports likely to rise.
New product launches.
Stable margins in key therapeutic categories.
Investment Advice: Hold long-term; monitor quarterly earnings growth.
By 2027, Jagsonpal Pharma may see stronger growth momentum.
Why?
Expansion of retail presence.
Rising healthcare demand in India.
Strengthening domestic and international partnerships.
Investment Advice: Long-term investors may reinvest dividends for compounding benefits.
In 2028, the company could cross the ₹400 mark comfortably.
Why?
Pharma industry CAGR remains strong.
Better return ratios expected.
Expansion of brand portfolio.
Investment Advice: Continue holding for long-term wealth creation.
By 2029, the company may benefit from rising demand in healthcare infrastructure.
Why?
Strong promoter backing (67.65%).
Stable revenue streams.
Pharma sector resilience against global slowdowns.
Investment Advice: Suitable for medium to long-term investors; expect moderate volatility.
By 2030, Jagsonpal Pharma may achieve significant growth, making it a potential multi-bagger in the mid-cap pharma space.
Why?
Robust presence in high-demand pharma segments.
Long-term growth in Indian and global pharmaceutical demand.
Strong balance sheet and consistent profitability.
Investment Advice: Excellent choice for long-term portfolios; good for wealth creation.
Yes, Jagsonpal Pharma is a promising stock for long-term investors, especially those seeking exposure in the growing healthcare and pharma sector.
Strong promoter holding (67.65%).
Dividend-paying with steady returns.
Pharma industry expected to grow steadily in India.
High volatility (Beta 1.65).
Price competition in the pharma industry.
Dependence on regulatory approvals and policies.
Jagsonpal Pharmaceuticals Ltd is a fundamentally strong pharma company with consistent dividend history, high promoter holding, and growing market presence. With its current price around ₹244, analysts expect the share to touch ₹600 by 2030 if growth strategies continue. For investors looking for steady long-term returns, Jagsonpal Pharma can be a strong addition to a diversified portfolio.
1. What is the next target of Jagsonpal Pharma?
The next target for Jagsonpal Pharma is around ₹250 – ₹270 by 2025.
2. Is Jagsonpal Pharma a good buy right now?
Yes, it is a good buy for long-term investors due to its strong fundamentals and dividend yield.
3. What will be the future outlook of Jagsonpal Pharma?
The outlook is positive with consistent demand for pharma products and global expansion opportunities.
4. What is the share price target for Jagsonpal Pharma in 2025?
The target is estimated between ₹250 – ₹270 in 2025.
5. What is the current Jagsonpal Pharma share price?
As of May 2025, it is around ₹244.
6. Is it a good time to buy Jagsonpal Pharma shares now?
Yes, for investors with a long-term horizon, current levels offer a good entry point.
7. Should I buy Jagsonpal Pharma stock?
Yes, it is suitable for long-term investors seeking exposure in the pharmaceutical sector.
8. How much has Jagsonpal Pharma increased from its 52-week low?
It has risen from ₹153.10 to ₹328.04, showing strong upside potential.
9. How do I invest in Jagsonpal Pharma?
You can buy shares through NSE/BSE via any registered stockbroker.
10. What is Jagsonpal Pharma’s shareholding pattern?
Promoters hold 67.65%, Retail & Others 30.12%, Foreign Institutions 2.18%, and Domestic Institutions 0.05%.
???? Disclaimer: This article is for educational purposes only. Please consult a financial advisor before making investment decisions.
Register & Login